A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

NCT03383458 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

545

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Liver Cancer

Interventions

BIOLOGICAL: Nivolumab
OTHER: Placebo

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]